首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2626335篇
  免费   194658篇
  国内免费   5001篇
耳鼻咽喉   36457篇
儿科学   88239篇
妇产科学   72518篇
基础医学   371786篇
口腔科学   74655篇
临床医学   233541篇
内科学   513558篇
皮肤病学   59212篇
神经病学   204688篇
特种医学   102262篇
外国民族医学   868篇
外科学   402575篇
综合类   59370篇
一般理论   849篇
预防医学   196633篇
眼科学   61378篇
药学   193745篇
  8篇
中国医学   5889篇
肿瘤学   147763篇
  2019年   19699篇
  2018年   28575篇
  2017年   21734篇
  2016年   23892篇
  2015年   27185篇
  2014年   38121篇
  2013年   56798篇
  2012年   78458篇
  2011年   82855篇
  2010年   49322篇
  2009年   46418篇
  2008年   77949篇
  2007年   83071篇
  2006年   83786篇
  2005年   80628篇
  2004年   78372篇
  2003年   74999篇
  2002年   72760篇
  2001年   133786篇
  2000年   137382篇
  1999年   114840篇
  1998年   29364篇
  1997年   25781篇
  1996年   26109篇
  1995年   26340篇
  1994年   24543篇
  1993年   22648篇
  1992年   89251篇
  1991年   86796篇
  1990年   83895篇
  1989年   80422篇
  1988年   73716篇
  1987年   72305篇
  1986年   67728篇
  1985年   64499篇
  1984年   47903篇
  1983年   40484篇
  1982年   23009篇
  1981年   20697篇
  1979年   42425篇
  1978年   29335篇
  1977年   24950篇
  1976年   23179篇
  1975年   24886篇
  1974年   29781篇
  1973年   28429篇
  1972年   26478篇
  1971年   24161篇
  1970年   22665篇
  1969年   20923篇
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
2.
3.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
4.
5.
Pharmaceutical Research - The quality testing and approval procedure for most pharmaceutical products is a streamlined process with standardized procedures for the determination of critical quality...  相似文献   
6.
Pharmaceutical Research - Cancer is associated with a comprehensive burden that significantly affects patient’s quality of life. Even though patients’ disease condition is improving...  相似文献   
7.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
8.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
9.
Journal of the Association for Research in Otolaryngology - Cochlear implant (CI) users show limited sensitivity to the temporal pitch conveyed by electric stimulation, contributing to impaired...  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号